NAS:NVCR () Also Trade In: Germany

NovoCure Ltd $ 145.62 -7.47 (-4.88%)

Volume:
1,342,399
Avg Vol (1m):
696,458
Market Cap $:
14.91 Bil
Enterprise Value $:
14.51 Bil
PE Ratio:
766.41
PB Ratio:
33.96
Warning! GuruFocus has detected 1 Severe warning sign with NVCR. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for NVCR (NovoCure Ltd) from 2015 to Mar 03 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. NovoCure stock (NVCR) PE ratio as of Mar 03 2021 is 766.41. More Details

NovoCure PE Ratio (TTM) Chart

EMBED

NovoCure PE Ratio (TTM) Historical Data

Total 1243
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
NovoCure PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-03-04766.4 2020-12-29889.3
2021-03-03766.4 2020-12-28893.6
2021-03-02805.7 2020-12-24905.1
2021-03-01802.3 2020-12-23898.5
2021-02-26784.7 2020-12-22900.0
2021-02-25783.7 2020-12-21891.9
2021-02-24911.2 2020-12-18843.1
2021-02-23910.3 2020-12-17856.9
2021-02-22952.8 2020-12-16827.0
2021-02-19NaN 2020-12-15826.8
2021-02-18924.8 2020-12-14889.4
2021-02-17952.1 2020-12-11903.7
2021-02-16975.3 2020-12-10885.2
2021-02-15998.2 2020-12-09847.5
2021-02-12998.2 2020-12-08828.8
2021-02-11963.6 2020-12-07801.7
2021-02-10962.2 2020-12-04776.3
2021-02-09984.4 2020-12-03710.8
2021-02-08968.2 2020-12-02685.4
2021-02-05925.5 2020-12-01668.3
2021-02-04921.2 2020-11-30661.3
2021-02-03916.0 2020-11-27667.6
2021-02-02915.4 2020-11-25614.1
2021-02-01853.5 2020-11-24628.5
2021-01-29847.2 2020-11-23707.4
2021-01-28849.0 2020-11-20696.6
2021-01-27824.1 2020-11-19659.3
2021-01-26866.1 2020-11-18640.6
2021-01-25880.0 2020-11-17641.8
2021-01-22890.0 2020-11-16632.0
2021-01-21904.4 2020-11-13655.2
2021-01-20907.3 2020-11-12650.1
2021-01-19885.7 2020-11-11644.8
2021-01-15881.8 2020-11-10625.0
2021-01-14941.8 2020-11-09661.7
2021-01-13931.3 2020-11-06664.4
2021-01-12925.3 2020-11-05643.1
2021-01-11895.2 2020-11-04641.8
2021-01-08896.7 2020-11-03599.1
2021-01-07861.0 2020-11-02590.3
2021-01-06829.1 2020-10-30642.6
2021-01-05855.8 2020-10-29648.8
2021-01-04849.1 2020-10-28607.3
2020-12-31910.7 2020-10-27629.0
2020-12-30916.5 2020-10-26639.5

NovoCure PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Medical Devices & Instruments » NAICS : 339112 NAICS : 3845
Traded in other countries 038.Germany NVCR.USA
Address Grenville Street, No. 4 The Forum, Saint Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.